raw_BioC_XML/PMC4848761_raw.xml

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201216</date><key>pmc.key</key><document><id>4848761</id><infon key="license">CC BY</infon><passage><infon key="alt-title">Jerome C Nwachukwu et al</infon><infon key="article-id_doi">10.15252/msb.20156701</infon><infon key="article-id_pmc">4848761</infon><infon key="article-id_pmid">27107013</infon><infon key="article-id_publisher-id">MSB156701</infon><infon key="elocation-id">864</infon><infon key="issue">4</infon><infon key="kwd">Breast cancer Chemical biology Crystal structure Nuclear receptor Signal transduction Chemical Biology Structural Biology Transcription</infon><infon key="license">This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon><infon key="name_0">surname:Nwachukwu;given-names:Jerome C</infon><infon key="name_1">surname:Srinivasan;given-names:Sathish</infon><infon key="name_10">surname:Carlson;given-names:Kathryn E</infon><infon key="name_11">surname:Josan;given-names:Jatinder S</infon><infon key="name_12">surname:Elemento;given-names:Olivier</infon><infon key="name_13">surname:Katzenellenbogen;given-names:John A</infon><infon key="name_14">surname:Zhou;given-names:Hai‐Bing</infon><infon key="name_15">surname:Nettles;given-names:Kendall W</infon><infon key="name_2">surname:Zheng;given-names:Yangfan</infon><infon key="name_3">surname:Wang;given-names:Song</infon><infon key="name_4">surname:Min;given-names:Jian</infon><infon key="name_5">surname:Dong;given-names:Chune</infon><infon key="name_6">surname:Liao;given-names:Zongquan</infon><infon key="name_7">surname:Nowak;given-names:Jason</infon><infon key="name_8">surname:Wright;given-names:Nicholas J</infon><infon key="name_9">surname:Houtman;given-names:René</infon><infon key="notes">

. () : 864
</infon><infon key="section_type">TITLE</infon><infon key="source">Mol Syst Biol</infon><infon key="title">Subject Categories</infon><infon key="type">front</infon><infon key="volume">12</infon><infon key="year">2016</infon><offset>0</offset><text>Predictive features of ligand‐specific signaling through the estrogen receptor</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>81</offset><text>Abstract</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>90</offset><text>Some estrogen receptor‐α (ERα)‐targeted breast cancer therapies such as tamoxifen have tissue‐selective or cell‐specific activities, while others have similar activities in different cell types. To identify biophysical determinants of cell‐specific signaling and breast cancer cell proliferation, we synthesized 241 ERα ligands based on 19 chemical scaffolds, and compared ligand response using quantitative bioassays for canonical ERα activities and X‐ray crystallography. Ligands that regulate the dynamics and stability of the coactivator‐binding site in the C‐terminal ligand‐binding domain, called activation function‐2 (AF‐2), showed similar activity profiles in different cell types. Such ligands induced breast cancer cell proliferation in a manner that was predicted by the canonical recruitment of the coactivators NCOA1/2/3 and induction of the GREB1 proliferative gene. For some ligand series, a single inter‐atomic distance in the ligand‐binding domain predicted their proliferative effects. In contrast, the N‐terminal coactivator‐binding site, activation function‐1 (AF‐1), determined cell‐specific signaling induced by ligands that used alternate mechanisms to control cell proliferation. Thus, incorporating systems structural analyses with quantitative chemical biology reveals how ligands can achieve distinct allosteric signaling outcomes through ERα.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1503</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1516</offset><text>Many drugs are small‐molecule ligands of allosteric signaling proteins, including G protein‐coupled receptors (GPCRs) and nuclear receptors such as ERα. These receptors regulate distinct phenotypic outcomes (i.e., observable characteristics of cells and tissues, such as cell proliferation or the inflammatory response) in a ligand‐dependent manner. Small‐molecule ligands control receptor activity by modulating recruitment of effector enzymes to distal regions of the receptor, relative to the ligand‐binding site. Some of these ligands achieve selectivity for a subset of tissue‐ or pathway‐specific signaling outcomes, which is called selective modulation, functional selectivity, or biased signaling, through structural mechanisms that are poorly understood (Frolik et al, 1996; Nettles &amp; Greene, 2005; Overington et al, 2006; Katritch et al, 2012; Wisler et al, 2014). For example, selective estrogen receptor modulators (SERMs) such as tamoxifen (Nolvadex®; AstraZeneca) or raloxifene (Evista®; Eli Lilly) (Fig 1A) block the ERα‐mediated proliferative effects of the native estrogen, 17β‐estradiol (E2), on breast cancer cells, but promote beneficial estrogenic effects on bone mineral density and adverse estrogenic effects such as uterine proliferation, fatty liver, or stroke (Frolik et al, 1996; Fisher et al, 1998; McDonnell et al, 2002; Jordan, 2003).</text></passage><passage><infon key="file">MSB-12-864-g002.jpg</infon><infon key="id">msb156701-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>2912</offset><text>Allosteric control of ERα activity</text></passage><passage><infon key="file">MSB-12-864-g002.jpg</infon><infon key="id">msb156701-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>2951</offset><text>Chemical structures of some common ERα ligands. BSC, basic side chain. E2‐rings are numbered A‐D. The E‐ring is the common site of attachment for BSC found in many SERMS.</text></passage><passage><infon key="file">MSB-12-864-g002.jpg</infon><infon key="id">msb156701-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>3129</offset><text>ERα domain organization lettered, A‐F. DBD, DNA‐binding domain; LBD, ligand‐binding domain; AF, activation function</text></passage><passage><infon key="file">MSB-12-864-g002.jpg</infon><infon key="id">msb156701-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>3252</offset><text>Schematic illustration of the canonical ERα signaling pathway.</text></passage><passage><infon key="file">MSB-12-864-g002.jpg</infon><infon key="id">msb156701-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>3319</offset><text>Linear causality model for ERα‐mediated cell proliferation.</text></passage><passage><infon key="file">MSB-12-864-g002.jpg</infon><infon key="id">msb156701-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>3383</offset><text>Branched causality model for ERα‐mediated cell proliferation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3449</offset><text>ERα contains structurally conserved globular domains of the nuclear receptor superfamily, including a DNA‐binding domain (DBD) that is connected by a flexible hinge region to the ligand‐binding domain (LBD), as well as unstructured AB and F domains at its amino and carboxyl termini, respectively (Fig 1B). The LBD contains a ligand‐dependent coactivator‐binding site called activation function‐2 (AF‐2). However, the agonist activity of SERMs derives from activation function‐1 (AF‐1)—a coactivator recruitment site located in the AB domain (Berry et al, 1990; Shang &amp; Brown, 2002; Abot et al, 2013).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4073</offset><text>AF‐1 and AF‐2 bind distinct but overlapping sets of coregulators (Webb et al, 1998; Endoh et al, 1999; Delage‐Mourroux et al, 2000; Yi et al, 2015). AF‐2 binds the signature LxxLL motif peptides of coactivators such as NCOA1/2/3 (also known as SRC‐1/2/3). AF‐1 binds a separate surface on these coactivators (Webb et al, 1998; Yi et al, 2015). Yet, it is unknown how different ERα ligands control AF‐1 through the LBD, and whether this inter‐domain communication is required for cell‐specific signaling or anti‐proliferative responses.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4636</offset><text>In the canonical model of the ERα signaling pathway (Fig 1C), E2‐bound ERα forms a homodimer that binds DNA at estrogen‐response elements (EREs), recruits NCOA1/2/3 (Metivier et al, 2003; Johnson &amp; O'Malley, 2012), and activates the GREB1 gene, which is required for proliferation of ERα‐positive breast cancer cells (Ghosh et al, 2000; Rae et al, 2005; Deschenes et al, 2007; Liu et al, 2012; Srinivasan et al, 2013). However, ERα‐mediated proliferative responses vary in a ligand‐dependent manner (Srinivasan et al, 2013); thus, it is not known whether this canonical model is widely applicable across diverse ERα ligands.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5284</offset><text>Our long‐term goal is to be able to predict proliferative or anti‐proliferative activity of a ligand in different tissues from its crystal structure by identifying different structural perturbations that lead to specific signaling outcomes. The simplest response model for ligand‐specific proliferative effects is a linear causality model, where the degree of NCOA1/2/3 recruitment determines GREB1 expression, which in turn drives ligand‐specific cell proliferation (Fig 1D). Alternatively, a more complicated branched causality model could explain ligand‐specific proliferative responses (Fig 1E). In this signaling model, multiple coregulator binding events and target genes (Won Jeong et al, 2012; Nwachukwu et al, 2014), LBD conformation, nucleocytoplasmic shuttling, the occupancy and dynamics of DNA binding, and other biophysical features could contribute independently to cell proliferation (Lickwar et al, 2012).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6222</offset><text>To test these signaling models, we profiled a diverse library of ERα ligands using systems biology approaches to X‐ray crystallography and chemical biology (Srinivasan et al, 2013), including a series of quantitative bioassays for ERα function that were statistically robust and reproducible, based on the Z’‐statistic (Fig EV1A and B; see Materials and Methods). We also determined the structures of 76 distinct ERα LBD complexes bound to different ligand types, which allowed us to understand how diverse ligand scaffolds distort the active conformation of the ERα LBD. Our findings here indicate that specific structural perturbations can be tied to ligand‐selective domain usage and signaling patterns, thus providing a framework for structure‐based design of improved breast cancer therapeutics, and understanding the different phenotypic effects of environmental estrogens.</text></passage><passage><infon key="file">MSB-12-864-g003.jpg</infon><infon key="id">msb156701-fig-0001ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>7118</offset><text>High‐throughput screens for ERα ligand profiling</text></passage><passage><infon key="file">MSB-12-864-g003.jpg</infon><infon key="id">msb156701-fig-0001ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>7171</offset><text>Summary of ligand screening assays used to measure ER‐mediated activities. ERE, estrogen‐response element; Luc, luciferase reporter gene; M2H, mammalian 2‐hybrid; UAS, upstream‐activating sequence.</text></passage><passage><infon key="file">MSB-12-864-g003.jpg</infon><infon key="id">msb156701-fig-0001ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>7377</offset><text>Controls for screening assays described in panel (A), above. Error bars indicate mean ± SEM, n = 3.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>7478</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>7486</offset><text>Strength of AF‐1 signaling does not determine cell‐specific signaling</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7560</offset><text>To compare ERα signaling induced by diverse ligand types, we synthesized and assayed a library of 241 ERα ligands containing 19 distinct molecular scaffolds. These include 15 indirect modulator series, which lack a SERM‐like side chain and modulate coactivator binding indirectly from the ligand‐binding pocket (Fig 2A–E; Dataset EV1) (Zheng et al, 2012) (Zhu et al, 2012) (Muthyala et al, 2003; Seo et al, 2006) (Srinivasan et al, 2013) (Wang et al, 2012) (Liao et al, 2014) (Min et al, 2013). We also generated four direct modulator series with side chains designed to directly dislocate h12 and thereby completely occlude the AF‐2 surface (Fig 2C and E; Dataset EV1) (Kieser et al, 2010). Ligand profiling using our quantitative bioassays revealed a wide range of ligand‐induced GREB1 expression, reporter gene activities, ERα‐coactivator interactions, and proliferative effects on MCF‐7 breast cancer cells (Figs EV1 and EV2A–J). This wide variance enabled us to probe specific features of ERα signaling using ligand class analyses, and identify signaling patterns shared by specific ligand series or scaffolds.</text></passage><passage><infon key="file">MSB-12-864-g004.jpg</infon><infon key="id">msb156701-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>8708</offset><text>Classes of compounds in the ERα ligand library</text></passage><passage><infon key="file">MSB-12-864-g004.jpg</infon><infon key="id">msb156701-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>8759</offset><text>Structure of the E2‐bound ERα LBD in complex with an NCOA2 peptide of (PDB 1GWR).</text></passage><passage><infon key="file">MSB-12-864-g004.jpg</infon><infon key="id">msb156701-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>8845</offset><text>Structural details of the ERα LBD bound to the indicated ligands. Unlike E2 (PDB 1GWR), TAM is a direct modulator with a BSC that dislocates h12 to block the NCOA2‐binding site (PDB 3ERT). OBHS is an indirect modulator that dislocates the h11 C‐terminus to destabilize the h11–h12 interface (PDB 4ZN9).</text></passage><passage><infon key="file">MSB-12-864-g004.jpg</infon><infon key="id">msb156701-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9155</offset><text>The ERα ligand library contains 241 ligands representing 15 indirect modulator scaffolds, plus 4 direct modulator scaffolds. The number of compounds per scaffold is shown in parentheses (see Dataset EV1 for individual compound information and Appendix Supplementary Methods for synthetic protocols).</text></passage><passage><infon key="file">MSB-12-864-g005.jpg</infon><infon key="id">msb156701-fig-0002ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>9459</offset><text>ERα ligands induced a range of agonist activity profiles</text></passage><passage><infon key="file">MSB-12-864-g005.jpg</infon><infon key="id">msb156701-fig-0002ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9520</offset><text>Screening data from individual ligands are shown, grouped by scaffold. Each data point represents the activity of a distinct compound. Error bars indicate the class average (mean) ± range. *Direct modulator.</text></passage><passage><infon key="file">MSB-12-864-g005.jpg</infon><infon key="id">msb156701-fig-0002ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9731</offset><text>
Source data are available online for this figure.
</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>9783</offset><text>We first asked whether direct modulation of the receptor with an extended side chain is required for cell‐specific signaling. To this end, we compared the average ligand‐induced GREB1 mRNA levels in MCF‐7 cells and 3×ERE‐Luc reporter gene activity in Ishikawa endometrial cancer cells (E‐Luc) or in HepG2 cells transfected with wild‐type ERα (L‐Luc ERα‐WT) (Figs 3A and EV2A–C). Direct modulators showed significant differences in average activity between cell types except OBHS‐ASC analogs, which had similar low agonist activities in the three cell types. The other direct modulators had low agonist activity in Ishikawa cells, no or inverse agonist activity in MCF‐7 cells, and more variable activity in HepG2 liver cells. While it was known that direct modulators such as tamoxifen drive cell‐specific signaling, these experiments reveal that indirect modulators also drive cell‐specific signaling, since eight of fourteen classes showed significant differences in average activity (Figs 3A and EV2A–C).</text></passage><passage><infon key="file">MSB-12-864-g006.jpg</infon><infon key="id">msb156701-fig-0003</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>10824</offset><text>Ligand‐specific signaling underlies ERα‐mediated cell proliferation</text></passage><passage><infon key="file">MSB-12-864-g006.jpg</infon><infon key="id">msb156701-fig-0003</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>10897</offset><text>(A) Ligand‐specific ERα activities in HepG2, Ishikawa and MCF‐7 cells. The ligand‐induced L‐Luc ERα‐WT and E‐Luc activities and GREB1 mRNA levels are shown by scaffold (mean + SD). (B) Ligand class analysis of the L‐Luc ERα‐WT and ERα‐ΔAB activities in HepG2 cells. Significant sensitivity to AB domain deletion was determined by Student's t‐test (n = number of ligands per scaffold in Fig 2). The average activities of ligands classes are shown (mean + SEM).</text></passage><passage><infon key="file">MSB-12-864-g006.jpg</infon><infon key="id">msb156701-fig-0003</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11389</offset><text>Correlation and regression analyses in a large test set. The r
2 values are plotted as a heat map. In cluster 1, the first three comparisons (rows) showed significant positive correlations (F‐test for nonzero slope, P ≤ 0.05). In cluster 2, only one of these comparisons revealed a significant positive correlation, while none was significant in cluster 3. +, statistically significant correlations gained by deletion of the AB or F domains. −, significant correlations lost upon deletion of AB or F domains.</text></passage><passage><infon key="file">MSB-12-864-g006.jpg</infon><infon key="id">msb156701-fig-0003</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11906</offset><text>
Source data are available online for this figure.
</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11958</offset><text>Tamoxifen depends on AF‐1 for its cell‐specific activity (Sakamoto et al, 2002); therefore, we asked whether cell‐specific signaling observed here is due to a similar dependence on AF‐1 for activity (Fig EV1). To test this idea, we compared the average L‐Luc activities of each scaffold in HepG2 cells co‐transfected with wild‐type ERα or with ERα lacking the AB domain (Figs 1B and EV1). While E2 showed similar L‐Luc ERα‐WT and ERα‐ΔAB activities, tamoxifen showed complete loss of activity without the AB domain (Fig EV1B). Deletion of the AB domain significantly reduced the average L‐Luc activities of 14 scaffolds (Student's t‐test, P ≤ 0.05) (Fig 3B). These “AF‐1‐sensitive” activities were exhibited by both direct and indirect modulators, and were not limited to scaffolds that showed cell‐specific signaling (Fig 3A and B). Thus, the strength of AF‐1 signaling does not determine cell‐specific signaling.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12926</offset><text>Identifying cell‐specific signaling clusters in ERα ligand classes</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12997</offset><text>As another approach to identifying cell‐specific signaling, we determined the degree of correlation between ligand‐induced activities in the different cell types. Here, we compared ligands within each class (Fig 3C), instead of comparing average activities (Fig 3A and B). For each ligand class or scaffold, we calculated the Pearson's correlation coefficient, r, for pairwise comparison of activity profiles in breast (GREB1), liver (L‐Luc), and endometrial cells (E‐Luc). The value of r ranges from −1 to 1, and it defines the extent to which the data fit a straight line when compounds show similar agonist/antagonist activity profiles between cell types (Fig EV3A). We also calculated the coefficient of determination, r 2, which describes the percentage of variance in a dependent variable such as proliferation that can be predicted by an independent variable such as GREB1 expression. We present both calculations as r 2 to readily compare signaling specificities using a heat map on which the red–yellow palette indicates significant positive correlations (P ≤ 0.05, F‐test for nonzero slope), while the blue palette denotes negative correlations (Fig 3C–F).</text></passage><passage><infon key="file">MSB-12-864-g007.jpg</infon><infon key="id">msb156701-fig-0003ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>14188</offset><text>The side chain of OBHS‐BSC analogs induces cell‐specific signaling</text></passage><passage><infon key="file">MSB-12-864-g007.jpg</infon><infon key="id">msb156701-fig-0003ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14259</offset><text>Correlation analysis of OBHS versus OBHS‐BSC activity across cell types.</text></passage><passage><infon key="file">MSB-12-864-g007.jpg</infon><infon key="id">msb156701-fig-0003ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14334</offset><text>Correlation analysis of L‐Luc ERα‐ΔAB activity versus endogenous ERα activity of OBHS analogs. In panel (D), L‐Luc ERα‐WT activity from panel (B) is shown for comparison.</text></passage><passage><infon key="file">MSB-12-864-g007.jpg</infon><infon key="id">msb156701-fig-0003ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14521</offset><text>Correlation analysis of L‐Luc ERα‐ΔF activity versus endogenous ERα activities of OBHS analogs.</text></passage><passage><infon key="file">MSB-12-864-g007.jpg</infon><infon key="id">msb156701-fig-0003ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14629</offset><text>Correlation analysis of MCF‐7 cell proliferation versus NCOA2/3 recruitment or GREB1 levels observed in response to (G) OBHS‐N and (H) OBHS‐BSC analogs.</text></passage><passage><infon key="file">MSB-12-864-g007.jpg</infon><infon key="id">msb156701-fig-0003ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14788</offset><text>
Data information: In each panel, a data point indicates the activity of a distinct compound.Source data are available online for this figure.
</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14932</offset><text>This analysis revealed diverse signaling specificities that we grouped into three clusters. Scaffolds in cluster 1 exhibited strongly correlated GREB1 levels, E‐Luc and L‐Luc activity profiles across the three cell types (Fig 3C lanes 1–4), suggesting these ligands use similar ERα signaling pathways in the breast, endometrial, and liver cell types. This cluster includes WAY‐C, OBHS, OBHS‐N, and triaryl‐ethylene analogs, all of which are indirect modulators. Cluster 2 contains scaffolds with activities that were positively correlated in only two of the three cell types, indicating cell‐specific signaling (Fig 3C lanes 5–12). This cluster includes two classes of direct modulators (cyclofenil‐ASC and WAY dimer), and six classes of indirect modulators (2,5‐DTP, 3,4‐DTP, S‐OBHS‐2 and S‐OBHS‐3, furan, and WAY‐D). In this cluster, the correlated activities varied by scaffold. For example, 3,4‐DTP, furan, and S‐OBHS‐2 drove positively correlated GREB1 levels and E‐Luc but not L‐Luc ERα‐WT activity (Fig 3C lanes 5–7). In contrast, WAY dimer and WAY‐D analogs drove positively correlated GREB1 levels and L‐Luc ERα‐WT but not E‐Luc activity (Fig 3C lanes 8 and 9). The last set of scaffolds, cluster 3, displayed cell‐specific activities that were not correlated in any of the three cell types (Fig 3C lanes 13–19). This cluster includes two direct modulator scaffolds (OBHS‐ASC and OBHS‐BSC), and five indirect modulator scaffolds (A‐CD, cyclofenil, 3,4‐DTPD, imine, and imidazopyridine).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16503</offset><text>These results suggest that addition of an extended side chain to an ERα ligand scaffold is sufficient to induce cell‐specific signaling, where the relative activity profiles of the individual ligands change between cell types. This is demonstrated by directly comparing the signaling specificities of matched OBHS (indirect modulator, cluster 1) and OBHS‐BSC analogs (direct modulator, cluster 3), which differ only in the basic side chain (Fig 2E). The activities of OBHS analogs were positively correlated across the three cell types, but the side chain of OBHS‐BSC analogs was sufficient to abolish these correlations (Figs 3C lanes 1 and 19, and EV3A–C).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17173</offset><text>The indirect modulator scaffolds in clusters 2 and 3 showed cell‐specific signaling patterns without the extended side chain typically viewed as the primary chemical and structural mechanism driving cell‐specific activity. Many of these scaffolds drove similar average activities of the ligand class in the different cell types (Fig 3A), but the individual ligands in each class had different cell‐specific activities (Fig EV2A–C). Thus, examining the correlated patterns of ERα activity within each scaffold demonstrates that an extended side chain is not required for cell‐specific signaling.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17781</offset><text>Modulation of signaling specificity by AF‐1</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17827</offset><text>To evaluate the role of AF‐1 and the F domain in ERα signaling specificity, we compared activity of truncated ERα constructs in HepG2 liver cells with endogenous ERα activity in the other cell types. The positive correlation between the L‐Luc and E‐Luc activities or GREB1 levels induced by scaffolds in cluster 1 was generally retained without the AB domain, or the F domain (Fig 3D lanes 1–4). This demonstrates that the signaling specificities underlying these positive correlations are not modified by AF‐1. OBHS analogs showed an average L‐Luc ERα‐ΔAB activity of 3.2% ± 3 (mean + SEM) relative to E2. Despite this nearly complete lack of activity, the pattern of L‐Luc ERα‐ΔAB activity was still highly correlated with the E‐Luc activity and GREB1 expression (Fig EV3D and E), demonstrating that very small AF‐2 activities can be amplified by AF‐1 to produce robust signals. Similarly, deletion of the F domain did not abolish correlations between the L‐Luc and E‐Luc or GREB1 levels induced by OBHS analogs (Fig EV3F). These similar patterns of ligand activity in the wild‐type and deletion mutants suggest that AF‐1 and the F domain purely amplify the AF‐2 activities of ligands in cluster 1.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19077</offset><text>In contrast, AF‐1 was a determinant of signaling specificity for scaffolds in cluster 2. Deletion of the AB or F domain altered correlations for six of the eight scaffolds in this cluster (2,5‐DTP, 3,4‐DTP, S‐OBHS‐3, WAY‐D, WAY dimer, and cyclofenil‐ASC) (Fig 3D lanes 5–12). Comparing Fig 3C and D, the + and − signs indicate where the deletion mutant assays led to a gain or loss of statically significant correlation, respectively. Thus, in cluster 2, AF‐1 substantially modulated the specificity of ligands with cell‐specific activity (Fig 3D lanes 5–12). For ligands in cluster 3, we could not eliminate a role for AF‐1 in determining signaling specificity, since this cluster lacked positively correlated activity profiles (Fig 3C), and deletion of the AB or F domain rarely induced such correlations (Fig 3D), except for A‐CD and OBHS‐ASC analogs, where deletion of the AB domain or F domain led to positive correlations with E‐Luc activity and/or GREB1 levels (Fig 3D lanes 13 and 18). Thus, ligands in cluster 2 rely on AF‐1 for both activity (Fig 3B) and signaling specificity (Fig 3D). As discussed below, this cell specificity derives from alternate coactivator preferences.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20306</offset><text>Ligand‐specific control of GREB1 expression</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20352</offset><text>To determine whether ligand classes control expression of native ERα target genes through the canonical linear signaling pathway, we performed pairwise linear regression analyses using ERα–NCOA1/2/3 interactions in M2H assay as independent predictors of GREB1 expression (the dependent variable) (Figs EV1 and EV2A, F–H). In cluster 1, the recruitment of NCOA1 and NCOA2 was highest for WAY‐C, followed by triaryl‐ethylene, OBHS‐N, and OBHS series, while for NCOA3, OBHS‐N compounds induced the most recruitment and OBHS ligands were inverse agonists (Fig EV2F–H). The average induction of GREB1 by cluster 1 ligands showed greater variance, with a range between ~25 and ~75% for OBHS and a range from full agonist to inverse agonist for the others in cluster 1 (Fig EV2A). GREB1 levels induced by OBHS analogs were determined by recruitment of NCOA1 but not NCOA2/3 (Fig 3E lane 1), suggesting that there may be alternate or preferential use of these coactivators by different classes. However, in cluster 1, NCOA1/2/3 recruitment generally predicted GREB1 levels (Fig 3E lanes 1–4), consistent with the canonical signaling model (Fig 1D).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21517</offset><text>For clusters 2 and 3, GREB1 activity was generally not predicted by NCOA1/2/3 recruitment. Direct modulators showed low NCOA1/2/3 recruitment (Fig EV2F–H), but only OBHS‐ASC analogs had NCOA2 recruitment profiles that predicted a full range of effects on GREB1 levels (Figs 3E lanes 9, 11, 18–19, and EV2A). The indirect modulators in clusters 2 and 3 stimulated NCOA1/2/3 recruitment and GREB1 expression with substantial variance (Figs 3A and EV2F–H). However, ligand‐induced GREB1 levels were generally not determined by NCOA1/2/3 recruitment (Fig 3E lanes 5–19), consistent with an alternate causality model (Fig 1E). Out of 11 indirect modulator series in cluster 2 or 3, only the S‐OBHS‐3 class had NCOA1/2/3 recruitment profiles that predicted GREB1 levels (Fig 3E lane 12). These results suggest that compounds that show cell‐specific signaling do not activate GREB1, or use coactivators other than NCOA1/2/3 to control GREB1 expression (Fig 1E).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>22497</offset><text>Ligand‐specific control of cell proliferation</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22545</offset><text>To determine mechanisms for ligand‐dependent control of breast cancer cell proliferation, we performed linear regression analyses across the 19 scaffolds using MCF‐7 cell proliferation as the dependent variable, and the other activities as independent variables (Fig 3F). In cluster 1, E‐Luc and L‐Luc activities, NCOA1/2/3 recruitment, and GREB1 levels generally predicted the proliferative response (Fig 3F lanes 2–4). With the OBHS‐N compounds, NCOA3 and GREB1 showed near perfect prediction of proliferation (Fig EV3G), with unexplained variance similar to the noise in the assays. The lack of significant predictors for OBHS analogs (Fig 3F lane 1) reflects their small range of proliferative effects on MCF‐7 cells (Fig EV2I). The significant correlations with GREB1 expression and NCOA1/2/3 recruitment observed in this cluster are consistent with the canonical signaling model (Fig 1D), where NCOA1/2/3 recruitment determines GREB1 expression, which then drives proliferation.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>23550</offset><text>Ligands in cluster 2 and cluster 3 showed a wide range of proliferative effects on MCF‐7 cells (Fig EV2I). Despite this phenotypic variance, proliferation was not generally predicted by correlated NCOA1/2/3 recruitment and GREB1 induction (Figs 3F lanes 5–19, and EV3H). Out of 15 ligand series in these clusters, only 2,5‐DTP analogs induced a proliferative response that was predicted by GREB1 levels, which were not determined by NCOA1/2/3 recruitment (Fig 3E and F lane 10). 3,4‐DTP, cyclofenil, 3,4‐DTPD, and imidazopyridine analogs had NCOA1/3 recruitment profiles that predicted their proliferative effects, without determining GREB1 levels (Fig 3E and F, lanes 5 and 14–16). Similarly, S‐OBHS‐3, cyclofenil‐ASC, and OBHS‐ASC had positively correlated NCOA1/2/3 recruitment and GREB1 levels, but none of these activities determined their proliferative effects (Fig 3E and F lanes 11–12 and 18). For ligands that show cell‐specific signaling, ERα‐mediated recruitment of other coregulators and activation of other target genes likely determine their proliferative effects on MCF‐7 cells.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>24678</offset><text>NCOA3 occupancy at GREB1 did not predict the proliferative response</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24746</offset><text>We also questioned whether promoter occupancy by coactivators is statistically robust and reproducible for ligand class analysis using a chromatin immunoprecipitation (ChIP)‐based quantitative assay, and whether it has a better predictive power than the M2H assay. ERα and NCOA3 cycle on and off the GREB1 promoter (Nwachukwu et al, 2014). Therefore, we first performed a time‐course study, and found that E2 and the WAY‐C analog, AAPII‐151‐4, induced recruitment of NCOA3 to the GREB1 promoter in a temporal cycle that peaked after 45 min in MCF‐7 cells (Fig 4A). At this time point, other WAY‐C analogs also induced recruitment of NCOA3 at this site to varying degrees (Fig 4B). The Z’ for this assay was 0.6, showing statistical robustness (see Materials and Methods). We prepared biological replicates with different cell passage numbers and separately prepared samples, which showed r 2 of 0.81, demonstrating high reproducibility (Fig 4C).</text></passage><passage><infon key="file">MSB-12-864-g008.jpg</infon><infon key="id">msb156701-fig-0004</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>25714</offset><text>
NCOA3 occupancy at GREB1 is statistically robust but does not predict transcriptional activity</text></passage><passage><infon key="file">MSB-12-864-g008.jpg</infon><infon key="id">msb156701-fig-0004</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>25810</offset><text>Kinetic ChIP assay examining recruitment of NCOA3 to the GREB1 gene in MCF‐7 cells stimulated with E2 or the indicated WAY‐C analog. The average of duplicate experiments (mean ± SEM) is shown.</text></passage><passage><infon key="file">MSB-12-864-g008.jpg</infon><infon key="id">msb156701-fig-0004</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>26010</offset><text>NCOA3 occupancy at GREB1 was compared by ChIP assay 45 min after stimulation with vehicle, E2, or the WAY‐C analogs. In panel (B), the average recruitment of two biological replicates are shown as mean + SEM, and the Z‐score is indicated. In panel (C), correlation analysis was performed for two biological replicates.</text></passage><passage><infon key="file">MSB-12-864-g008.jpg</infon><infon key="id">msb156701-fig-0004</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>26336</offset><text>Linear regression analyses comparing the ability of NCOA3 recruitment, measured by ChIP or M2H, to predict other agonist activities of WAY‐C analogs. *Significant positive correlation (F‐test for nonzero slope, P‐value).</text></passage><passage><infon key="file">MSB-12-864-g008.jpg</infon><infon key="id">msb156701-fig-0004</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>26563</offset><text>
Source data are available online for this figure.
</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>26615</offset><text>The M2H assay for NCOA3 recruitment broadly correlated with the other assays, and was predictive for GREB1 expression and cell proliferation (Fig 3E). However, the ChIP assays for WAY‐C‐induced recruitment of NCOA3 to the GREB1 promoter did not correlate with any of the other WAY‐C activity profiles (Fig 4D), although the positive correlation between ChIP assays and NCOA3 recruitment via M2H assay showed a trend toward significance with r 2 = 0.36 and P = 0.09 (F‐test for nonzero slope). Thus, the simplified coactivator‐binding assay showed much greater predictive power than the ChIP assay for ligand‐specific effects on GREB1 expression and cell proliferation.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>27302</offset><text>ERβ activity is not an independent predictor of cell‐specific activity</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>27376</offset><text>One difference between MCF‐7 breast cancer cells and Ishikawa endometrial cancer cells is the contribution of ERβ to estrogenic response, as Ishikawa cells may express ERβ (Bhat &amp; Pezzuto, 2001). When overexpressed in MCF‐7 cells, ERβ alters E2‐induced expression of only a subset of ERα‐target genes (Wu et al, 2011), raising the possibility that ligand‐induced ERβ activity may contribute to E‐Luc activities, and thus underlie the lack of correlation between the E‐Luc and L‐Luc ERα‐WT activities or GREB1 levels induced by cell‐specific modulators in cluster 2 and cluster 3 (Fig 3C).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>27993</offset><text>To test this idea, we determined the L‐Luc ERβ activity profiles of the ligands (Fig EV1). All direct modulator and two indirect modulator scaffolds (OBHS and S‐OBHS‐3) lacked ERβ agonist activity. However, the other ligands showed a range of ERβ activities (Fig EV2J). For most scaffolds, L‐Luc ERβ and E‐Luc activities were not correlated, except for 2,5‐DTP and cyclofenil analogs, which showed moderate but significant correlations (Fig EV4A). Nevertheless, the E‐Luc activities of both 2,5‐DTP and cyclofenil analogs were better predicted by their L‐Luc ERα‐WT than L‐Luc ERβ activities (Fig EV4A and B). Thus, ERβ activity was not an independent determinant of the observed activity profiles.</text></passage><passage><infon key="file">MSB-12-864-g009.jpg</infon><infon key="id">msb156701-fig-0004ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>28725</offset><text>ERβ activity is not an independent predictor of E‐Luc activity</text></passage><passage><infon key="file">MSB-12-864-g009.jpg</infon><infon key="id">msb156701-fig-0004ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>28791</offset><text>ERβ activity in HepG2 cells rarely correlates with E‐Luc activity.</text></passage><passage><infon key="file">MSB-12-864-g009.jpg</infon><infon key="id">msb156701-fig-0004ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>28861</offset><text>ERα activity of 2,5‐DTP and cyclofenil analogs correlates with E‐Luc activity.</text></passage><passage><infon key="file">MSB-12-864-g009.jpg</infon><infon key="id">msb156701-fig-0004ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>28945</offset><text>
Data information: The r
2 and P values for the indicated correlations are shown in both panels. *Significant positive correlation (F‐test for nonzero slope, P‐value)</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>29116</offset><text>Structural features of consistent signaling across cell types</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>29178</offset><text>To overcome barriers to crystallization of ERα LBD complexes, we developed a conformation‐trapping X‐ray crystallography approach using the ERα‐Y537S mutation (Nettles et al, 2008; Bruning et al, 2010; Srinivasan et al, 2013). To further validate this approach, we solved the structure of the ERα‐Y537S LBD in complex with diethylstilbestrol (DES), which bound identically in the wild‐type and ERα‐Y537S LBDs, demonstrating again that this surface mutation stabilizes h12 dynamics to facilitate crystallization without changing ligand binding (Appendix Fig S1A and B) (Nettles et al, 2008; Bruning et al, 2010; Delfosse et al, 2012). Using this approach, we solved 76 ERα LBD structures in the active conformation and bound to ligands studied here (Appendix Fig S1C). Eleven of these structures have been published, while 65 are new, including the DES‐bound ERα‐Y537S LBD. We present 57 of these new structures here (Dataset EV2), while the remaining eight new structures bound to OBHS‐N analogs will be published elsewhere (S. Srinivasan et al, in preparation). Examining many closely related structures allows us to visualize subtle structural differences, in effect using X‐ray crystallography as a systems biology tool.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>30436</offset><text>The indirect modulator scaffolds in cluster 1 did not show cell‐specific signaling (Fig 3C), but shared common structural perturbations that we designed to modulate h12 dynamics. Based on our original OBHS structure, the OBHS, OBHS‐N, and triaryl‐ethylene compounds were modified with h11‐directed pendant groups (Zheng et al, 2012; Zhu et al, 2012; Liao et al, 2014). Superposing the LBDs based on the class of bound ligands provides an ensemble view of the structural variance and clarifies what part of the ligand‐binding pocket is differentially perturbed or targeted.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>31023</offset><text>The 24 structures containing OBHS, OBHS‐N, or triaryl‐ethylene analogs showed structural diversity in the same part of the scaffolds (Figs 5A and EV5A), and the same region of the LBD—the C‐terminal end of h11 (Figs 5B and C, and EV5B), which in turn nudges h12 (Fig 5C and D). We observed that the OBHS‐N analogs displaced h11 along a vector away from Leu354 in a region of h3 that is unaffected by the ligands, and toward the dimer interface. For the triaryl‐ethylene analogs, the displacement of h11 was in a perpendicular direction, away from Ile424 in h8 and toward h12. Remarkably, these individual inter‐atomic distances showed a ligand class‐specific ability to significantly predict proliferative effects (Fig 5E and F), demonstrating the feasibility of developing a minimal set of activity predictors from crystal structures.</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>31879</offset><text>Structural determinants of consistent signaling</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>31927</offset><text>Structure‐class analysis of triaryl‐ethylene analogs. Triaryl‐ethylene analogs bound to the superposed crystal structures of the ERα LBD are shown. Arrows indicate chemical variance in the orientation of the different h11‐directed ligand side groups (PDB 5DK9, 5DKB, 5DKE, 5DKG, 5DKS, 5DL4, 5DLR, 5DMC, 5DMF and 5DP0).</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>32255</offset><text>Triaryl‐ethylene analogs induce variance of ERα conformations at the C‐terminal region of h11. Panel (B) shows the crystal structure of a triaryl‐ethylene analog‐bound ERα LBD (PDB 5DLR). The h11–h12 interface (circled) includes the C‐terminal part of h11. This region was expanded in panel (C), where the 10 triaryl‐ethylene analog‐bound ERα LBD structures (see Datasets EV1 and EV2) were superposed to show variations in the h11 C‐terminus (PDB 5DK9, 5DKB, 5DKE, 5DKG, 5DKS, 5DL4, 5DLR, 5DMC, 5DMF, and 5DP0).</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>32789</offset><text>ERα LBDs in complex with diethylstilbestrol (DES) or a triaryl‐ethylene analog were superposed to show that the ligand‐induced difference in h11 conformation is transmitted to the C‐terminus of h12 (PDB 4ZN7, 5DMC).</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33012</offset><text>Inter‐atomic distances predict the proliferative effects of specific ligand series. Ile424–His524 distance measured in the crystal structures correlates with the proliferative effect of triaryl‐ethylene analogs in MCF‐7 cells. In contrast, the Leu354–Leu525 distance correlates with the proliferative effects of OBHS‐N analogs in MCF‐7 cells.</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33369</offset><text>Structure‐class analysis of WAY‐C analogs. WAY‐C side groups subtly nudge h12 Leu540. ERα LBD structures bound to 4 distinct WAY‐C analogs were superposed (PDB 4 IU7, 4IV4, 4IVW, 4IW6) (see Datasets EV1 and EV2).</text></passage><passage><infon key="file">MSB-12-864-g010.jpg</infon><infon key="id">msb156701-fig-0005</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33592</offset><text>
Source data are available online for this figure.
</text></passage><passage><infon key="file">MSB-12-864-g011.jpg</infon><infon key="id">msb156701-fig-0005ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>33644</offset><text>Structure‐class analysis of indirect modulators</text></passage><passage><infon key="file">MSB-12-864-g011.jpg</infon><infon key="id">msb156701-fig-0005ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33694</offset><text>Structure‐class analysis of indirect modulators in cluster 1. Crystal structures of the ERα LBD bound to OBHS and OBHS‐N analogs were superposed. The bound ligands are shown in panel (A). Arrows indicate chemical variance in the orientation of the different h11‐directed ligand side groups. Panel (B) shows the ligand‐induced conformational variation at the C‐terminal region of h11 (OBHS: PDB 4ZN9, 4ZNH, 4ZNS, 4ZNT, 4ZNU, 4ZNV, and 4ZNW; OBHS‐N: PDB 4ZUB, 4ZUC, 4ZWH, 4ZWK, 5BNU, 5BP6, 5BPR, and 5BQ4).</text></passage><passage><infon key="file">MSB-12-864-g011.jpg</infon><infon key="id">msb156701-fig-0005ev</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>34213</offset><text>Structure‐class analysis of indirect modulators in clusters 2 and 3. Crystal structures of the ERα LBD bound to ligands with cell‐specific activities were superposed. The bound ligands are shown, and arrows indicate considerable variation in the orientation of the different h3‐, h8‐, h11‐, or h12‐directed ligand side groups.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>34553</offset><text>As visualized in four LBD structures (Srinivasan et al, 2013), WAY‐C analogs were designed with small substitutions that slightly nudge h12 Leu540, without exiting the ligand‐binding pocket (Fig 5G and H). Therefore, changing h12 dynamics maintains the canonical signaling pathway defined by E2 (Fig 1D) to support AF‐2‐driven signaling and recruit NCOA1/2/3 for GREB1‐stimulated proliferation.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>34961</offset><text>Ligands with cell‐specific activity alter the shape of the AF‐2 surface</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>35037</offset><text>Direct modulators like tamoxifen drive AF‐1‐dependent cell‐specific activity by completely occluding AF‐2, but it is not known how indirect modulators produce cell‐specific ERα activity. Therefore, we examined another 50 LBD structures containing ligands in clusters 2 and 3. These structures demonstrated that cell‐specific activity derived from altering the shape of the AF‐2 surface without an extended side chain.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>35470</offset><text>Ligands in cluster 2 and cluster 3 showed conformational heterogeneity in parts of the scaffold that were directed toward multiple regions of the receptor including h3, h8, h11, h12, and/or the β‐sheets (Fig EV5C–G). For instance, S‐OBHS‐2 and S‐OBHS‐3 analogs (Fig 2) had similar ERα activity profiles in the different cell types (Fig EV2A–C), but the 2‐ versus 3‐methyl substituted phenol rings altered the correlated signaling patterns in different cell types (Fig 3B lanes 7 and 12). Structurally, the 2‐ versus 3‐methyl substitutions changed the binding position of the A‐ and E‐ring phenols by 1.0 Å and 2.2 Å, respectively (Fig EV5C). This difference in ligand positioning altered the AF‐2 surface via a shift in the N‐terminus of h12, which directly contacts the coactivator. This effect is evident in a single structure due to its 1 Å magnitude (Fig 6A and B). The shifts in h12 residues Asp538 and Leu539 led to rotation of the coactivator peptide (Fig 6C). Thus, cell‐specific activity can stem from perturbation of the AF‐2 surface without an extended side chain, which presumably alters the receptor–coregulator interaction profile.</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_title_caption</infon><offset>36665</offset><text>Structural correlates of cell‐specific signaling</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>36716</offset><text>S‐OBHS‐2/3 analogs subtly distort the AF‐2 surface. Panel (A) shows the crystal structure of an S‐OBHS‐3‐bound ERα LBD (PDB 5DUH). The h3–h12 interface (circled) at AF‐2 (pink) was expanded in panels (B, C). The S‐OBHS‐2/3‐bound ERα LBDs were superposed to show shifts in h3 (panel B) and the NCOA2 peptide docked at the AF‐2 surface (panel C).</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>37088</offset><text>Crystal structures show that 2,5‐DTP analogs shift h3 and h11 further apart compared to an A‐CD‐ring estrogen (PDB 4PPS, 5DRM, 5DRJ). The 2F
o‐F
c electron density map and F
o‐F
c difference map of a 2,5‐DTP‐bound structure (PDB 5DRJ) were contoured at 1.0 sigma and ± 3.0 sigma, respectively.</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>37398</offset><text>Average (mean + SEM) α‐carbon distance measured from h3 Thr347 to h11 Leu525 of A‐CD‐, 2,5‐DTP‐, and 3,4‐DTPD‐bound ERα LBDs. *Two‐tailed Student's t‐test, P = 0.002 (PDB A‐CD: 5DI7, 5DID, 5DIE, 5DIG, and 4PPS; 2,5‐DTP: 4IWC, 5DRM, and 5DRJ; 3,4‐DTPD: 5DTV and 5DU5).</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>37696</offset><text>Crystal structures show that a 3,4‐DTPD analog shifts h3 (F) and the NCOA2 (G) peptide compared to an A‐CD‐ring estrogen (PDB 4PPS, 5DTV).</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>37841</offset><text>Hierarchical clustering of ligand‐specific binding of 154 interacting peptides to the ERα LBD was performed in triplicate by MARCoNI analysis.</text></passage><passage><infon key="file">MSB-12-864-g012.jpg</infon><infon key="id">msb156701-fig-0006</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>37988</offset><text>
Source data are available online for this figure.
</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>38040</offset><text>The 2,5‐DTP analogs showed perturbation of h11, as well as h3, which forms part of the AF‐2 surface. These compounds bind the LBD in an unusual fashion because they have a phenol‐to‐phenol length of ~12 Å, which is longer than steroids and other prototypical ERα agonists that are ~10 Å in length. One phenol pushed further toward h3 (Fig 6D), while the other phenol pushed toward the C‐terminus of h11 to a greater extent than A‐CD‐ring estrogens (Nwachukwu et al, 2014), which are close structural analogs of E2 that lack a B‐ring (Fig 2). To quantify this difference, we compared the distance between α‐carbons at h3 Thr347 and h11 Leu525 in the set of structures containing 2,5‐DTP analogs (n = 3) or A‐CD‐ring analogs (n = 5) (Fig 6E). We observed a difference of 0.4 Å that was significant (two‐tailed Student's t‐test, P = 0.002) due to the very tight clustering of the 2,5‐DTP‐induced LBD conformation. The shifts in h3 suggest these compounds are positioned to alter coregulator preferences.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>39088</offset><text>The 2,5‐DTP and 3,4‐DTP scaffolds are isomeric, but with aryl groups at obtuse and acute angles, respectively (Fig 2). The crystal structure of ERα in complex with a 3,4‐DTP is unknown; however, we solved two crystal structures of ERα bound to 3,4‐DTPD analogs and one structure containing a furan ligand—all of which have a 3,4‐diaryl configuration (Fig 2; Datasets EV1 and EV2). In these structures, the A‐ring mimetic of the 3,4‐DTPD scaffold bound h3 Glu353 as expected, but the other phenol wrapped around h3 to form a hydrogen bond with Thr347, indicating a change in binding epitopes in the ERα ligand‐binding pocket (Fig 6F). The 3,4‐DTPD analogs also induced a shift in h3 positioning, which translated again into a shift in the bound coactivator peptide (Fig 6F). Therefore, these indirect modulators, including S‐OBHS‐2, S‐OBHS‐3, 2,5‐DTP, and 3,4‐DTPD analogs—all of which show cell‐specific activity profiles—induced shifts in h3 and h12 that were transmitted to the coactivator peptide via an altered AF‐2 surface.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>40164</offset><text>To test whether the AF‐2 surface shows changes in shape in solution, we used the microarray assay for real‐time coregulator–nuclear receptor interaction (MARCoNI) analysis (Aarts et al, 2013). Here, the ligand‐dependent interactions of the ERα LBD with over 150 distinct LxxLL motif peptides were assayed to define structural fingerprints for the AF‐2 surface, in a manner similar to the use of phage display peptides as structural probes (Connor et al, 2001). Despite the similar average activities of these ligand classes (Fig 3A and B), 2,5‐DTP and 3,4‐DTP analogs displayed remarkably different peptide recruitment patterns (Fig 6H), consistent with the structural analyses.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>40862</offset><text>Hierarchical clustering revealed that many of the 2,5‐DTP analogs recapitulated most of the peptide recruitment and dismissal patterns observed with E2 (Fig 6H). However, there was a unique cluster of peptides that were recruited by E2 but not the 2,5‐DTP analogs. In contrast, 3,4‐DTP analogs dismissed most of the peptides from the AF‐2 surface (Fig 6H). Thus, the isomeric attachment of diaryl groups to the thiophene core changed the AF‐2 surface from inside the ligand‐binding pocket, as predicted by the crystal structures. Together, these findings suggest that without an extended side chain, cell‐specific activity stems from different coregulator recruitment profiles, due to unique ligand‐induced conformations of the AF‐2 surface, in addition to differential usage of AF‐1. Indirect modulators in cluster 1 avoid this by perturbing the h11–h12 interface, and modulating the dynamics of h12 without changing the shape of AF‐2 when stabilized.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>41841</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>41852</offset><text>Our goal was to identify a minimal set of predictors that would link specific structural perturbations to ERα signaling pathways that control cell‐specific signaling and proliferation. We found a very strong set of predictors, where ligands in cluster 1, defined by similar signaling across cell types, showed indirect modulation of h12 dynamics via the h11–12 interface or slight contact with h12. This perturbation determined proliferation that correlated strongly with AF‐2 activity, recruitment of NCOA1/2/3 family members, and induction of the GREB1 gene, consistent with the canonical ERα signaling pathway (Fig 1D). For ligands in cluster 1, deletion of AF‐1 reduced activity to varying degrees, but did not change the underlying signaling patterns established through AF‐2. In contrast, an extended side chain designed to directly reposition h12 and completely disrupt the AF‐2 surface results in cell‐specific signaling. This was demonstrated with direct modulators in clusters 2 and 3. Cluster 2 was defined by ligand classes that showed correlated activities in two of the three cell types tested, while ligand classes in cluster 3 did not show correlated activities among any of the three cell types. Compared to cluster 1, the structural rules are less clear in clusters 2 and 3, but a number of indirect modulator classes perturbed the LBD conformation at the intersection of h3, the h12 N‐terminus, and the AF‐2 surface. Ligands in these classes altered the shape of AF‐2 to affect coregulator preferences. For direct and indirect modulators in cluster 2 or 3, the canonical ERα signaling pathway involving recruitment of NCOA1/2/3 and induction of GREB1 did not generally predict their proliferative effects, indicating an alternate causal model (Fig 1E).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>43650</offset><text>These principles outlined above provide a structural basis for how the ligand–receptor interface leads to different signaling specificities through AF‐1 and AF‐2. It is noteworthy that regulation of h12 dynamics indirectly through h11 can virtually abolish AF‐2 activity, and yet still drive robust transcriptional activity through AF‐1, as demonstrated with the OBHS series. This finding can be explained by the fact that NCOA1/2/3 contain distinct binding sites for interaction with AF‐1 and AF‐2 (McInerney et al, 1996; Webb et al, 1998), which allows ligands to nucleate ERα–NCOA1/2/3 interaction through AF‐2, and reinforce this interaction with additional binding to AF‐1. Completely blocking AF‐2 with an extended side chain or altering the shape of AF‐2 changes the preference away from NCOA1/2/3 for determining GREB1 levels and proliferation of breast cancer cells. AF‐2 blockade also allows AF‐1 to function independently, which is important since AF‐1 drives tissue‐selective effects in vivo. This was demonstrated with AF‐1 knockout mice that show E2‐dependent vascular protection, but not uterine proliferation, thus highlighting the role of AF‐1 in tissue‐selective or cell‐specific signaling (Billon‐Gales et al, 2009; Abot et al, 2013).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>44954</offset><text>One current limitation to our approach is the identification of statistical variables that predict ligand‐specific activity. Here, we examined many LBD structures and tested several variables that were not predictive, including ERβ activity, the strength of AF‐1 signaling, and NCOA3 occupancy at the GREB1 gene. Similarly, we visualized structures to identify patterns. There are many systems biology approaches that could contribute to the unbiased identification of predictive variables for statistical modeling. For example, phage display was used to identify the androgen receptor interactome, which was cloned into an M2H library and used to identify clusters of ligand‐selective interactions (Norris et al, 2009). Also, we have used siRNA screening to identify a number of coregulators required for ERα‐mediated repression of the IL‐6 gene (Nwachukwu et al, 2014). However, the use of larger datasets to identify such predictor variables has its own limitations, one of the major ones being the probability of false positives from multiple hypothesis testing. If we calculated inter‐atomic distance matrices containing 4,000 atoms per structure × 76 ligand–receptor complexes, we would have 3 × 105 predictions. One way to address this issue is to use the cross‐validation concept, where hypotheses are generated on training sets of ligands and tested with another set of ligands.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>46367</offset><text>Based on this work, we propose several testable hypotheses for drug discovery. We have identified atomic vectors for the OBHS‐N and triaryl‐ethylene classes that predict ligand response (Fig 5E and F). These ligands in cluster 1 drive consistent, canonical signaling across cell types, which is desirable for generating full antagonists. Indeed, the most anti‐proliferative compound in the OBHS‐N series had a fulvestrant‐like profile across a battery of assays (S. Srinivasan et al, in preparation). Secondly, our finding that WAY‐C compounds do not rely of AF‐1 for signaling efficacy may derive from the slight contacts with h12 observed in crystal structures (Figs 3B and 5H), unlike other compounds in cluster 1 that dislocate h11 and rely on AF‐1 for signaling efficacy (Figs 3B and 5C, and EV5B). Thirdly, we found ligands that achieved cell‐specific activity without a prototypical extended side chain. Some of these ligands altered the shape of the AF‐2 surface by perturbing the h3–h12 interface, thus providing a route to new SERM‐like activity profiles by combining indirect and direct modulation of receptor structure. Incorporation of statistical approaches to understand relationships between structure and signaling variables moves us toward predictive models for complex ERα‐mediated responses such as in vivo uterine proliferation or tumor growth, and more generally toward structure‐based design for other allosteric drug targets including GPCRs and other nuclear receptors.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>47895</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>47917</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>47938</offset><text>Correlation and linear regression analyses were performed using GraphPad Prism software. For correlation analysis, the degree to which two datasets vary together was calculated with the Pearson correlation coefficient (r). However, we reported r 2 rather than r, to facilitate comparison with the linear regression results for which we calculated and reported r 2 (Fig 3C–F). Significance for r 2 was determined using the F‐test for nonzero slope. High‐throughput assays were considered statistically robust if they show Z’ &gt; 0.5, where Z’ = 1 − (3(σp+σn)/|μp−μn|), for the mean (σ) and standard deviations (μ) of the positive and negative controls (Fig EV1A and B).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>48631</offset><text>ERα ligand library</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>48654</offset><text>The library of compounds examined includes both previously reported (Srinivasan et al, 2013) and newly synthesized compound series (see Dataset EV1 for individual compound information, and Appendix Supplementary Methods for synthetic protocols).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>48902</offset><text>Luciferase reporter assays</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>48929</offset><text>Cells were transfected with FugeneHD reagent (Roche Applied Sciences, Indianapolis, IN) in 384‐well plates. After 24 h, cells were stimulated with 10 μM compounds dispensed using a 100‐nl pintool Biomeck NXP workstation (Beckman Coulter Inc.). Luciferase activity was measured 24 h later (see Appendix Supplementary Methods for more details).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>49281</offset><text>Mammalian 2‐hybrid (M2H) assays</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>49315</offset><text>HEK293T cells were transfected with 5× UAS‐luciferase reporter, and wild‐type ERα‐VP16 activation domain plus full‐length NCOA1/2/3‐GAL4 DBD fusion protein expression plasmids, using the TransIT‐LT1 transfection reagent (Mirus Bio LLC, Madison, WI). The next day, cells were stimulated with 10 μM compounds using a 100‐nl pintool Biomeck NXP workstation (Beckman Coulter Inc.). Luciferase activity was measured after 24 h (see Appendix Supplementary Methods for more details).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>49813</offset><text>Cell proliferation assay</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>49838</offset><text>MCF‐7 cells were plated on 384‐well plates in phenol red‐free media plus 10% FBS and stimulated with 10 μM compounds using 100‐nl pintool Biomeck NXP workstation (Beckman Coulter Inc.). Cell numbers determined 1 week later (see Appendix Supplementary Methods for more details).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>50128</offset><text>Quantitative RT–PCR</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>50150</offset><text>MCF‐7 cells were steroid‐deprived and stimulated with compounds for 24 h. Total RNA was extracted and reverse‐transcribed. The cDNA was analyzed using TaqMan Gene Expression Master Mix (Life Technologies, Grand Island, NY), GREB1 and GAPDH (control) primers, and hybridization probes (see Appendix Supplementary Methods for more details).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>50497</offset><text>MARCoNI coregulator‐interaction profiling</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>50541</offset><text>This assay was performed as previously described with the ERα LBD, 10 μM compounds, and a PamChiP peptide microarray (PamGene International) containing 154 unique coregulator peptides (Aarts et al, 2013) (see Appendix Supplementary Methods for more details).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>50805</offset><text>Protein production and X‐ray crystallography</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>50852</offset><text>ERα protein was produced as previously described (Bruning et al, 2010). New ERα LBD structures (see Dataset EV2 for data collection and refinement statistics) were solved by molecular replacement using PHENIX (Adams et al, 2010), refined using ExCoR as previously described (Nwachukwu et al, 2013), and COOT (Emsley &amp; Cowtan, 2004) for ligand‐docking and rebuilding.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>51227</offset><text>Data availability</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>51245</offset><text>Crystal structures analyzed in this study include the following: 1GWR (Warnmark et al, 2002), 3ERD and 3ERT (Shiau et al, 1998), 4ZN9 (Zheng et al, 2012), 4IWC, 4 IU7, 4IV4, 4IVW, 4IW6, 4IUI, 4IV2, 4IVY and 4IW8 (Srinivasan et al, 2013), and 4PPS (Nwachukwu et al, 2014). New crystal structures analyzed in this study were deposited in the RCSB protein data bank (http://www.pdb.org): 4ZN7, 4ZNH, 4ZNS, 4ZNT, 4ZNU, 4ZNV, 4ZNW, 5DI7, 5DID, 5DIE, 5DIG, 5DK9, 5DKB, 5DKE, 5DKG, 5DKS, 5DL4, 5DLR, 5DMC, 5DMF, 5DP0, 5DRM, 5DRJ, 5DTV, 5DU5, 5DUE, 5DUG, 5DUH, 5DXK, 5DXM, 5DXP, 5DXQ, 5DXR, 5EHJ, 5DY8, 5DYB, 5DYD, 5DZ0, 5DZ1, 5DZ3, 5DZH, 5DZI, 5E0W, 5E0X, 5E14, 5E15, 5E19, 5E1C, 5DVS, 5DVV, 5DWE, 5DWG, 5DWI, 5DWJ, 5EGV, 5EI1, 5EIT.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>51978</offset><text>Author contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>51999</offset><text>JCN and SS contributed equally to this work. JCN and SS designed and performed experiments and wrote the manuscript; YZ, KEC, SW, JM, CD, ZL, VC, JN, NJW, JSJ, and RH performed experiments; HBZ designed experiments; and JAK and KWN designed experiments and wrote the manuscript.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>52278</offset><text>Conflict of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>52299</offset><text>The authors declare that they have no conflict of interest.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>52359</offset><text>Supporting information</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>52382</offset><text>References</text></passage><passage><infon key="fpage">336</infon><infon key="lpage">346</infon><infon key="pub-id_pmid">23383871</infon><infon key="section_type">REF</infon><infon key="source">Chem Res Toxicol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2013</infon><offset>52393</offset><text>Robust array‐based coregulator binding assay predicting ERalpha‐agonist potency and generating binding profiles reflecting ligand structure</text></passage><passage><infon key="fpage">2222</infon><infon key="lpage">2233</infon><infon key="pub-id_pmid">23580568</infon><infon key="section_type">REF</infon><infon key="source">Endocrinology</infon><infon key="type">ref</infon><infon key="volume">154</infon><infon key="year">2013</infon><offset>52537</offset><text>The AF‐1 activation function of estrogen receptor alpha is necessary and sufficient for uterine epithelial cell proliferation in vivo</text></passage><passage><infon key="fpage">213</infon><infon key="lpage">221</infon><infon key="pub-id_pmid">20124702</infon><infon key="section_type">REF</infon><infon key="source">Acta Crystallogr D Biol Crystallogr</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">2010</infon><offset>52674</offset><text>PHENIX: a comprehensive Python‐based system for macromolecular structure solution</text></passage><passage><infon key="fpage">2811</infon><infon key="lpage">2818</infon><infon key="pub-id_pmid">2118104</infon><infon key="section_type">REF</infon><infon key="source">EMBO J</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">1990</infon><offset>52758</offset><text>Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen</text></passage><passage><infon key="fpage">6137</infon><infon key="lpage">6144</infon><infon key="pub-id_pmid">11507064</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2001</infon><offset>52935</offset><text>Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells</text></passage><passage><infon key="fpage">2053</infon><infon key="lpage">2058</infon><infon key="pub-id_pmid">19188600</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">106</infon><infon key="year">2009</infon><offset>53052</offset><text>The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta‐estradiol</text></passage><passage><infon key="fpage">837</infon><infon key="lpage">843</infon><infon key="pub-id_pmid">20924370</infon><infon key="section_type">REF</infon><infon key="source">Nat Chem Biol</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2010</infon><offset>53181</offset><text>Coupling of receptor conformation and ligand orientation determine graded activity</text></passage><passage><infon key="fpage">2917</infon><infon key="lpage">2922</infon><infon key="pub-id_pmid">11306468</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2001</infon><offset>53264</offset><text>Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</text></passage><passage><infon key="fpage">35848</infon><infon key="lpage">35856</infon><infon key="pub-id_pmid">10960470</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">275</infon><infon key="year">2000</infon><offset>53404</offset><text>Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA</text></passage><passage><infon key="fpage">14930</infon><infon key="lpage">14935</infon><infon key="pub-id_pmid">22927406</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">109</infon><infon key="year">2012</infon><offset>53571</offset><text>Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes</text></passage><passage><infon key="fpage">17335</infon><infon key="lpage">17339</infon><infon key="pub-id_pmid">17463000</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">282</infon><infon key="year">2007</infon><offset>53710</offset><text>Regulation of GREB1 transcription by estrogen receptor alpha through a multipartite enhancer spread over 20 kb of upstream flanking sequences</text></passage><passage><infon key="fpage">2126</infon><infon key="lpage">2132</infon><infon key="pub-id_pmid">15572765</infon><infon key="section_type">REF</infon><infon key="source">Acta Crystallogr D Biol Crystallogr</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">2004</infon><offset>53853</offset><text>Coot: model‐building tools for molecular graphics</text></passage><passage><infon key="fpage">5363</infon><infon key="lpage">5372</infon><infon key="pub-id_pmid">10409727</infon><infon key="section_type">REF</infon><infon key="source">Mol Cell Biol</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1999</infon><offset>53905</offset><text>Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha</text></passage><passage><infon key="fpage">1371</infon><infon key="lpage">1388</infon><infon key="pub-id_pmid">9747868</infon><infon key="section_type">REF</infon><infon key="source">J Natl Cancer Inst</infon><infon key="type">ref</infon><infon key="volume">90</infon><infon key="year">1998</infon><offset>54069</offset><text>Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‐1 Study</text></passage><passage><infon key="fpage">621</infon><infon key="lpage">627</infon><infon key="pub-id_pmid">8806005</infon><infon key="section_type">REF</infon><infon key="source">Bone</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1996</infon><offset>54190</offset><text>Time‐dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate</text></passage><passage><infon key="fpage">6367</infon><infon key="lpage">6375</infon><infon key="pub-id_pmid">11103799</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">2000</infon><offset>54353</offset><text>PDZK1 and GREB1 are estrogen‐regulated genes expressed in hormone‐responsive breast cancer</text></passage><passage><infon key="fpage">430</infon><infon key="lpage">439</infon><infon key="pub-id_pmid">21664237</infon><infon key="section_type">REF</infon><infon key="source">Mol Cell Endocrinol</infon><infon key="type">ref</infon><infon key="volume">348</infon><infon key="year">2012</infon><offset>54448</offset><text>Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)‐based cancer therapy</text></passage><passage><infon key="fpage">883</infon><infon key="lpage">908</infon><infon key="pub-id_pmid">12620065</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">2003</infon><offset>54600</offset><text>Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions</text></passage><passage><infon key="fpage">17</infon><infon key="lpage">27</infon><infon key="pub-id_pmid">22032986</infon><infon key="section_type">REF</infon><infon key="source">Trends Pharmacol Sci</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">2012</infon><offset>54712</offset><text>Diversity and modularity of G protein‐coupled receptor structures</text></passage><passage><infon key="fpage">3320</infon><infon key="lpage">3329</infon><infon key="pub-id_pmid">20334372</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">2010</infon><offset>54780</offset><text>Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs)</text></passage><passage><infon key="fpage">3532</infon><infon key="lpage">3545</infon><infon key="pub-id_pmid">24708493</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2014</infon><offset>54889</offset><text>Triaryl‐substituted Schiff bases are high‐affinity subtype‐selective ligands for the estrogen receptor</text></passage><passage><infon key="fpage">251</infon><infon key="lpage">255</infon><infon key="pub-id_pmid">22498630</infon><infon key="section_type">REF</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="volume">484</infon><infon key="year">2012</infon><offset>54998</offset><text>Genome‐wide protein‐DNA binding dynamics suggest a molecular clutch for transcription factor function</text></passage><passage><infon key="fpage">e46410</infon><infon key="pub-id_pmid">23056300</infon><infon key="section_type">REF</infon><infon key="source">PLoS ONE</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2012</infon><offset>55104</offset><text>GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer</text></passage><passage><infon key="fpage">295</infon><infon key="lpage">316</infon><infon key="pub-id_pmid">12017549</infon><infon key="section_type">REF</infon><infon key="source">Recent Prog Horm Res</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2002</infon><offset>55188</offset><text>Definition of the molecular and cellular mechanisms underlying the tissue‐selective agonist/antagonist activities of selective estrogen receptor modulators</text></passage><passage><infon key="fpage">10069</infon><infon key="lpage">10073</infon><infon key="pub-id_pmid">8816752</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci USA</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">1996</infon><offset>55346</offset><text>Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator</text></passage><passage><infon key="fpage">751</infon><infon key="lpage">763</infon><infon key="pub-id_pmid">14675539</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">2003</infon><offset>55446</offset><text>Estrogen receptor‐alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter</text></passage><passage><infon key="fpage">3346</infon><infon key="lpage">3366</infon><infon key="pub-id_pmid">23586645</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">56</infon><infon key="year">2013</infon><offset>55571</offset><text>Thiophene‐core estrogen receptor ligands having superagonist activity</text></passage><passage><infon key="fpage">1589</infon><infon key="lpage">1602</infon><infon key="pub-id_pmid">12699377</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">2003</infon><offset>55643</offset><text>Bridged bicyclic cores containing a 1,1‐diarylethylene motif are high‐affinity subtype‐selective ligands for the estrogen receptor</text></passage><passage><infon key="fpage">309</infon><infon key="lpage">333</infon><infon key="pub-id_pmid">15709961</infon><infon key="section_type">REF</infon><infon key="source">Annu Rev Physiol</infon><infon key="type">ref</infon><infon key="volume">67</infon><infon key="year">2005</infon><offset>55780</offset><text>Ligand control of coregulator recruitment to nuclear receptors</text></passage><passage><infon key="fpage">241</infon><infon key="lpage">247</infon><infon key="pub-id_pmid">18344977</infon><infon key="section_type">REF</infon><infon key="source">Nat Chem Biol</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2008</infon><offset>55843</offset><text>NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses</text></passage><passage><infon key="fpage">452</infon><infon key="lpage">460</infon><infon key="pub-id_pmid">19389631</infon><infon key="section_type">REF</infon><infon key="source">Chem Biol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2009</infon><offset>55943</offset><text>Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands</text></passage><passage><infon key="fpage">1923</infon><infon key="lpage">1930</infon><infon key="pub-id_pmid">24076406</infon><infon key="section_type">REF</infon><infon key="source">Structure</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2013</infon><offset>56079</offset><text>Improved crystallographic structures using extensive combinatorial refinement</text></passage><passage><infon key="fpage">e02057</infon><infon key="pub-id_pmid">24771768</infon><infon key="section_type">REF</infon><infon key="source">eLife</infon><infon key="type">ref</infon><infon key="volume">3</infon><infon key="year">2014</infon><offset>56157</offset><text>Resveratrol modulates the inflammatory response via an estrogen receptor‐signal integration network</text></passage><passage><infon key="fpage">993</infon><infon key="lpage">996</infon><infon key="pub-id_pmid">17139284</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Drug Discov</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2006</infon><offset>56259</offset><text>How many drug targets are there?</text></passage><passage><infon key="fpage">141</infon><infon key="lpage">149</infon><infon key="pub-id_pmid">15986123</infon><infon key="section_type">REF</infon><infon key="source">Breast Cancer Res Treat</infon><infon key="type">ref</infon><infon key="volume">92</infon><infon key="year">2005</infon><offset>56292</offset><text>GREB 1 is a critical regulator of hormone dependent breast cancer growth</text></passage><passage><infon key="fpage">93</infon><infon key="lpage">104</infon><infon key="pub-id_pmid">12088871</infon><infon key="section_type">REF</infon><infon key="source">Mol Cell Endocrinol</infon><infon key="type">ref</infon><infon key="volume">192</infon><infon key="year">2002</infon><offset>56365</offset><text>Estrogen receptor‐mediated effects of tamoxifen on human endometrial cancer cells</text></passage><passage><infon key="fpage">2496</infon><infon key="lpage">2511</infon><infon key="pub-id_pmid">16610793</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">2006</infon><offset>56449</offset><text>Fluorine‐substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure‐affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer</text></passage><passage><infon key="fpage">2465</infon><infon key="lpage">2468</infon><infon key="pub-id_pmid">11923541</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">295</infon><infon key="year">2002</infon><offset>56676</offset><text>Molecular determinants for the tissue specificity of SERMs</text></passage><passage><infon key="fpage">927</infon><infon key="lpage">937</infon><infon key="pub-id_pmid">9875847</infon><infon key="section_type">REF</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">1998</infon><offset>56735</offset><text>The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</text></passage><passage><infon key="fpage">326</infon><infon key="lpage">332</infon><infon key="pub-id_pmid">23524984</infon><infon key="section_type">REF</infon><infon key="source">Nat Chem Biol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2013</infon><offset>56853</offset><text>Ligand‐binding dynamics rewire cellular signaling via estrogen receptor‐alpha</text></passage><passage><infon key="fpage">2324</infon><infon key="lpage">2341</infon><infon key="pub-id_pmid">22283328</infon><infon key="section_type">REF</infon><infon key="source">J Med Chem</infon><infon key="type">ref</infon><infon key="volume">55</infon><infon key="year">2012</infon><offset>56935</offset><text>Identification and structure‐activity relationships of a novel series of estrogen receptor ligands based on 7‐thiabicyclo[2.2.1]hept‐2‐ene‐7‐oxide</text></passage><passage><infon key="fpage">21862</infon><infon key="lpage">21868</infon><infon key="pub-id_pmid">11937504</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">277</infon><infon key="year">2002</infon><offset>57094</offset><text>Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha</text></passage><passage><infon key="fpage">1605</infon><infon key="lpage">1618</infon><infon key="pub-id_pmid">9773983</infon><infon key="section_type">REF</infon><infon key="source">Mol Endocrinol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">1998</infon><offset>57238</offset><text>Estrogen receptor activation function 1 works by binding p160 coactivator proteins</text></passage><passage><infon key="fpage">18</infon><infon key="lpage">24</infon><infon key="pub-id_pmid">24680426</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Cell Biol</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2014</infon><offset>57321</offset><text>Recent developments in biased agonism</text></passage><passage><infon key="fpage">955</infon><infon key="lpage">966</infon><infon key="pub-id_pmid">22543272</infon><infon key="section_type">REF</infon><infon key="source">Mol Endocrinol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2012</infon><offset>57359</offset><text>Gene‐specific patterns of coregulator requirements by estrogen receptor‐alpha in breast cancer cells</text></passage><passage><infon key="fpage">R27</infon><infon key="pub-id_pmid">21392396</infon><infon key="section_type">REF</infon><infon key="source">Breast Cancer Res</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2011</infon><offset>57464</offset><text>Estrogen receptor‐beta sensitizes breast cancer cells to the anti‐estrogenic actions of endoxifen</text></passage><passage><infon key="fpage">1047</infon><infon key="lpage">1058</infon><infon key="pub-id_pmid">25728767</infon><infon key="section_type">REF</infon><infon key="source">Mol Cell</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2015</infon><offset>57566</offset><text>Structure of a biologically active estrogen receptor‐coactivator complex on DNA</text></passage><passage><infon key="fpage">1094</infon><infon key="lpage">1100</infon><infon key="pub-id_pmid">22517684</infon><infon key="section_type">REF</infon><infon key="source">ChemMedChem</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2012</infon><offset>57648</offset><text>Development of selective estrogen receptor modulator (SERM)‐like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7‐oxabicyclo[2.2.1]hept‐5‐ene scaffold core ligands</text></passage><passage><infon key="fpage">8692</infon><infon key="lpage">8700</infon><infon key="pub-id_pmid">23033157</infon><infon key="section_type">REF</infon><infon key="source">Org Biomol Chem</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2012</infon><offset>57874</offset><text>Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure‐activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides</text></passage></document></collection>